Unicancer

This study tests whether a drug called ribociclib can safely replace chemotherapy for women with a common type of early breast cancer (HR+ HER2-). About 3,900 women at intermediate risk of recurrence will receive either standard hormone therapy plus ribociclib or hormone therapy …

This phase 3 trial is testing whether giving a targeted therapy after initial standard chemotherapy can help people with advanced biliary cancer live longer without their disease getting worse. Participants must have a tumor with a specific genetic change and stable disease after…

This study tests a new drug called ivonescimab against standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has worsened after initial treatment. About 72 participants who were in the SAFIR-ABC10 trial will be randomly assigned to receive either ivonescim…

This Phase 3 trial tests whether adding darolutamide (Nubeqa) to standard hormone therapy (ADT) helps men with metastatic prostate cancer who are too frail for stronger treatments. About 300 participants will receive either darolutamide or a placebo, plus ADT. The goal is to see …

This Phase 2 trial tests whether adding the immunotherapy drug ivonescimab to standard chemotherapy can improve tumor shrinkage in people with advanced or metastatic stomach or gastroesophageal cancer. About 88 participants will receive treatment every two weeks. The main goal is…

This study tests whether adjusting chemotherapy doses based on a patient's DPD enzyme activity can reduce severe side effects in people with digestive cancers. About 400 participants with DPD deficiency will receive lower doses of fluoropyrimidine chemo (with oxaliplatin) and be …

This phase 2 trial tests injecting two immunotherapy drugs (ipilimumab and nivolumab) directly into melanoma tumors before surgical removal. The goal is to shrink or eliminate the cancer while reducing the severe side effects that can occur when these drugs are given through a ve…

This study tests giving immunotherapy before surgery for cancers that haven't spread. It uses a rapid blood and tumor test to match each patient to the treatment most likely to work for them. The goal is to shrink tumors, boost the immune system, and lower the chance of cancer co…

This trial tests whether adding liver-directed chemotherapy (GEMOX) to a two-drug immunotherapy regimen (durvalumab plus tremelimumab) improves outcomes for people with advanced liver cancer that has a high tumor burden. About 196 participants will be randomly assigned to receive…

This phase 2 trial tests zanidatamab, a drug that targets cancer cells with a HER2 gene alteration, in 105 adults with advanced lung, endometrial, colorectal, head & neck, or sarcoma cancers. Participants receive the drug every 3 weeks, and doctors monitor tumor shrinkage and sid…

This study tests a different chemotherapy drug (trifluridine/tipiracil) for people with metastatic colorectal or gastroesophageal cancer who have a genetic condition (DPD deficiency) that makes standard chemo very toxic. About 73 participants will receive this drug along with oth…

This phase 2 trial is testing whether the immunotherapy drug dostarlimab can work better than standard chemotherapy as a first treatment for people with rare, advanced cancers that have a specific genetic flaw called dMMR/MSI. The study includes 120 adults with cancers like pancr…

This phase 2 trial tests whether adding pembrolizumab (an immunotherapy) to capecitabine (chemotherapy) after standard treatment can prevent triple-negative breast cancer from coming back. It includes 220 adults who still have cancer after initial chemo-immunotherapy. Participant…

This phase 2 trial is for people with early-stage triple-negative breast cancer that has a high level of immune cells (TILs) in the tumor. It tests whether some patients can safely skip chemotherapy and just be monitored, while others receive a combination of the immunotherapy dr…

This study tests a combination of two oral chemotherapy drugs (tucatinib and capecitabine) plus a targeted antibody given directly into the spinal fluid (trastuzumab) for people with HER2-positive breast cancer that has spread to the lining of the brain and spinal cord (leptomeni…

This study tests whether a blood test that looks for HPV DNA can help monitor patients treated for HPV-related oropharyngeal cancer. The goal is to see if the test can detect cancer recurrence earlier than standard methods, and also reduce the number of routine follow-up visits f…

This study tests a virtual program that includes webinars and online visits to help women at high risk for breast cancer adopt healthier lifestyles. The goal is to see if women will stick with the program and whether it helps them reduce their risk. About 1,500 women from a large…

This study tests whether a digital platform called Cureety TechCare can improve quality of life and reduce hospitalizations for people with metastatic triple-negative breast cancer starting first-line treatment. Participants will regularly report symptoms through the platform, wh…

This study gathers information from the medical records of 75,000 adults treated for lung cancer at 38 French hospitals. Researchers will look at patient details, tumor types, and treatments given over time. The goal is to understand how care has evolved and what outcomes patient…

This study gathers information from over 42,000 people with metastatic breast cancer treated at 18 French cancer centers since 2008. Researchers will look at how treatments have changed over time and how they affect survival. The goal is to learn from real-world data to improve f…

This study tests whether an artificial intelligence tool can predict a breast cancer patient's risk of developing arm lymphedema (swelling) after radiation therapy. About 724 women will be randomly assigned to either see their personalized risk prediction or not. The goal is to s…

This study is collecting medical information and blood samples from 400 people with metastatic colorectal cancer that has a specific genetic change called BRAFV600E. The goal is to learn more about how this cancer is treated in everyday practice and what outcomes patients experie…

This study looks at how well certain markers in tumors can predict whether a type of targeted cancer treatment called antibody-drug conjugates (ADCs) will work. About 400 adults with advanced breast, stomach, bladder, or lung cancer will provide tumor samples before and after tre…